CytRx Corporation - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 51

CytRx Corporation – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “CytRx Corporation - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- CytRx Corporation - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of CytRx Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of CytRx Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the CytRx Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate CytRx Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of CytRx Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the CytRx Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with CytRx Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of CytRx Corporation and identify potential opportunities in those areas.

List of Tables
List of Figures
CytRx Corporation Snapshot
CytRx Corporation Overview
Key Information
Key Facts
CytRx Corporation – Research and Development Overview
Key Therapeutic Areas
CytRx Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
CytRx Corporation – Pipeline Products Glance
CytRx Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
CytRx Corporation–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
CytRx Corporation – Drug Profiles
Arimoclomol
Product Description
Mechanism of Action
R&D Progress
Tamibarotene
Product Description
Mechanism of Action
R&D Progress
Chaperone Regulators
Product Description
Mechanism of Action
R&D Progress
DP6-001 Vaccine
Product Description
Mechanism of Action
R&D Progress
INNO-206
Product Description
Mechanism of Action
R&D Progress
INNO-305
Product Description
Mechanism of Action
R&D Progress
Iroxanadine
Product Description
Mechanism of Action
R&D Progress
Arimoclomol
Product Description
Mechanism of Action
R&D Progress
INNO-206
Product Description
Mechanism of Action
R&D Progress
CytRx Corporation – Pipeline Analysis
CytRx Corporation – Pipeline Products by Therapeutic Class
CytRx Corporation Pipeline Products By Target
CytRx Corporation – Pipeline Products by Route of Administration
CytRx Corporation – Pipeline Products by Molecule Type
CytRx Corporation – Recent Pipeline Updates
CytRx Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
INNO-105
INNO-206
CytRx Corporation – Company Statement
CytRx Corporation – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jul 22, 2010: CytRx's Tamibarotene Eradicates Cancer In Advanced Acute Promyelocytic Leukemia After Failure Of Other Therapies
May 03, 2010: CytRx's INNO-206 Rapidly Shrinks Human Tumors In Animal Model Of Multiple Myeloma
Jan 06, 2010: CytRx Announces Plan To Initiate A Phase 2 Clinical Trial With INNO-206 For The Treatment Of Advanced Pancreatic Cancer
Dec 02, 2009: CytRx Announces That FDA Lifts Clinical Hold Of Arimoclomol In Amyotrophic Lateral Sclerosis
Nov 24, 2009: Cytrx Announces Plans To Initiate A Phase 2 Clinical Trial With Inno-206 In Patients With Advanced Soft Tissue Sarcomas
Sep 14, 2009: CytRx Corporation Announces Initiation Of A Dose Escalation Study
Sep 10, 2009: CytRx Receives FDA Letter Regarding The Phase IIb Trial For Arimoclomol .
Jun 29, 2009: CytRx Reports Favorable Progress Update For Its Pivotal Phase 2 Clinical Trial With Tamibarotene As A Third-line Treatment For Acute Promyelocytic Leukemia
Jun 17, 2009: CytRx's Tamibarotene Demonstrates Statistically Significant Anti-Tumor Activity In Animal Trial For Multiple Myeloma
Mar 18, 2009: CytRx Announces Significant Efficacy Results In A Pre-Clinical Trial With Iroxanadine For Diabetic Peripheral Neuropathy
Financial Deals Landscape
CytRx Corporation, Deals Summary, 2004 to 2010
CytRx Corporation Detailed Deal Summary
Acquisition
CytRx Acquires INNOVIVE PHARMACEUTICALS
Equity Offering
CytRx Completes Public Offering Of $20 Million
CytRx Completes Private Placement Of $37 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• Education Services - Global Strategic Business Report
• eLEARNING - Global Strategic Business Report
• Private Tutoring - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Charter Schools - Global Outlook
• International Military and Government Helicopter Survey